Humacyte Inc tiene un precio objetivo de consenso de $10.5 basado en las calificaciones de 12 analistas. El máximo es $25, emitido por D. Boral Capital el noviembre 13, 2025. El mínimo es $3, emitido por HC Wainwright & Co. el agosto 12, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por Benchmark, D. Boral Capital y D. Boral Capital el noviembre 13, 2025, noviembre 13, 2025 y noviembre 12, 2025, respectivamente. Con un precio objetivo promedio de $20.33 entre Benchmark, D. Boral Capital y D. Boral Capital, hay una 1546.42% upside implícita para Humacyte Inc según estas calificaciones más recientes de analistas.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/13/2025 | 790.69% | Benchmark | $14 → $11 | Maintains | Buy | |||
11/13/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
11/12/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
11/10/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
10/13/2025 | 385.83% | BTIG | $7 → $6 | Maintains | Buy | |||
10/06/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
09/30/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
09/18/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
09/15/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
08/27/2025 | 183.4% | Barclays | → $3.5 | Initiates | → Overweight | |||
08/12/2025 | 183.4% | TD Cowen | $5 → $3.5 | Maintains | Buy | |||
08/12/2025 | 142.91% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy | |||
08/11/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
07/23/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
07/09/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
06/09/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
05/14/2025 | 223.89% | HC Wainwright & Co. | → $4 | Assumes | → Buy | |||
05/14/2025 | 1033.6% | Benchmark | $17 → $14 | Maintains | Buy | |||
05/13/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
03/31/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
03/28/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
03/26/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
03/12/2025 | 1114.57% | HC Wainwright & Co. | $15 → $15 | Reiterates | Buy → Buy | |||
03/07/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
02/27/2025 | 1276.52% | Benchmark | $17 → $17 | Reiterates | Buy → Buy | |||
02/27/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
02/26/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
01/21/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
01/13/2025 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
12/23/2024 | 1276.52% | Benchmark | $15 → $17 | Maintains | Buy | |||
12/20/2024 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
12/20/2024 | 1114.57% | HC Wainwright & Co. | $12 → $15 | Reiterates | Buy → Buy | |||
11/21/2024 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
11/18/2024 | 871.66% | HC Wainwright & Co. | $12 → $12 | Reiterates | Buy → Buy | |||
11/13/2024 | 871.66% | HC Wainwright & Co. | $12 → $12 | Reiterates | Buy → Buy | |||
11/11/2024 | 1924.29% | D. Boral Capital | $25 → $25 | Maintains | Buy | |||
11/05/2024 | 871.66% | HC Wainwright & Co. | $6 → $12 | Maintains | Buy | |||
10/28/2024 | 1924.29% | EF Hutton | $25 → $25 | Maintains | Buy | |||
10/18/2024 | 709.72% | TD Cowen | $10 → $10 | Reiterates | Buy → Buy | |||
10/18/2024 | 709.72% | BTIG | $10 → $10 | Reiterates | Buy → Buy | |||
10/10/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
10/01/2024 | 1924.29% | EF Hutton | $25 → $25 | Maintains | Buy | |||
09/20/2024 | 952.63% | Cantor Fitzgerald | $13 → $13 | Reiterates | Overweight → Overweight | |||
09/09/2024 | 1924.29% | EF Hutton | → $25 | Initiates | → Buy | |||
09/05/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
08/14/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
08/12/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
07/15/2024 | 790.69% | BTIG | $8 → $11 | Maintains | Buy | |||
07/02/2024 | 466.8% | Cantor Fitzgerald | $7 → $7 | Reiterates | Overweight → Overweight | |||
07/02/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
05/24/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
05/13/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
04/01/2024 | 466.8% | Cantor Fitzgerald | $7 → $7 | Reiterates | Overweight → Overweight | |||
03/26/2024 | 223.89% | Piper Sandler | $4 → $4 | Maintains | Neutral | |||
03/25/2024 | 1114.57% | Benchmark | $15 → $15 | Reiterates | Buy → Buy | |||
03/08/2024 | 223.89% | Piper Sandler | $3 → $4 | Maintains | Neutral | |||
12/27/2023 | 1114.57% | Benchmark | $16 → $15 | Maintains | Buy | |||
12/11/2023 | 385.83% | HC Wainwright & Co. | → $6 | Initiates | → Buy | |||
11/10/2023 | 142.91% | Piper Sandler | $3.5 → $3 | Maintains | Neutral | |||
09/21/2023 | 466.8% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight | |||
08/31/2023 | 385.83% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight | |||
08/24/2023 | 385.83% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight | |||
08/15/2023 | 1195.55% | Benchmark | → $16 | Reiterates | Buy → Buy | |||
06/22/2023 | 385.83% | Cantor Fitzgerald | → $6 | Initiates | → Overweight | |||
06/12/2023 | 1195.55% | Benchmark | → $16 | Reiterates | Buy → Buy | |||
03/27/2023 | 1195.55% | Benchmark | → $16 | Reiterates | → Buy |
El último precio objetivo de Humacyte (NASDAQ:HUMA) fue comunicado por Benchmark el noviembre 13, 2025. La firma de analistas fijó un precio objetivo para $11.00 que espera HUMA a rise dentro de 12 meses (un posible 790.69% upside). 34 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Humacyte (NASDAQ:HUMA) fue proporcionada por Benchmark, y Humacyte mantuvo su buy calificación.
No hay última actualización para Humacyte
No hay una última revisión a la baja para Humacyte.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Humacyte, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Humacyte se registró el noviembre 13, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 13, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Humacyte (HUMA) fue un mantuvo con un precio objetivo de $14.00 a $11.00. El precio actual al que cotiza Humacyte (HUMA) es de $1.24, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.